• Jaudah Al-Maghrabi and Mohamad N Khabaz.
• From the Department of Pathology (Al-Maghrabi), Faculty of Medicine; from the Department of Pathology (Khabaz), Rabigh Faculty of Medicine, King Abdulaziz University, and from the Department of Pathology (Al-Maghrabi), King Faisal Specialist Hospital and Research Centre, Jeddah, Kingdom of Saudi Arabia.
• Saudi Med J. 2022 Jul 1; 43 (7): 687693687-693.

ObjectivesTo assess the immunohistochemistry phenotype of cyclooxygenase-2 (COX-2) in breast cancer (BC) and to correlate it with histological and clinical prognostic factors.MethodsThis retrospective study utilized COX-2 monoclonal antibody in an immunohistochemistry staining of tissue microarrays slides of 570 cases of previously diagnosed BC and with 52 of normal breast tissues from breast specimens resected for benign lesions or reconstruction (fibroadenoma and normal breast epithelium). This project was carried out in the Laboratory of pathology, King Abdulaziz University, Jeddah, Saudi Arabia, between September 2019 and September 2021.ResultsThe present data showed an important connection between the COX-2 expression phenotype and BC compared to benign breast tissues (p=0.034). The expression pattern of COX-2 was allied significantly with some factors which distinguished aggressive subtypes of BC, such as stage, distant metastases, lymphovascular invasion, and poor survival.ConclusionCyclooxygenase-2 is a valuable marker that could facilitate BC diagnosis and prognosis.Copyright: © Saudi Medical Journal.

13 keywords...

hide…